BioXcel Therapeutics Receives Positive Preliminary Meeting Comments from FDA

Strategic Insights -

BioXcel Therapeutics, Inc., a biopharmaceutical company, has received positive preliminary meeting comments from the U.S. Food and Drug Administration (FDA) regarding its planned pre-sNDA meeting scheduled for August 20, 2025. The company is evaluating the feedback and plans to provide an update next week. The meeting is aimed at gaining alignment with the FDA on the proposed format and content of the company's planned sNDA submission, which includes clinical, nonclinical, and chemistry, manufacturing, and controls (CMC) requirements.

Key Takeaways:

  • BioXcel Therapeutics received positive preliminary meeting comments from the FDA on August 14, 2025.
  • The company will use the feedback to evaluate and provide an update next week.
  • The primary purpose of the planned pre-sNDA meeting is to gain alignment with the FDA on the proposed sNDA submission.
  • The submission will cover clinical, nonclinical, and chemistry, manufacturing, and controls (CMC) requirements.
  • BioXcel Therapeutics is listed on the Nasdaq Capital Market under the ticker symbol BTAI.

Statistics:

  • The pre-sNDA meeting is scheduled to take place on August 20, 2025.
  • BioXcel Therapeutics is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (SS230.405).

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025